Announcement on Subsidiary Obtaining Drug Registration Certificate

Zhejiang Garden Bio-chemical High-tech Co., Ltd.·July 1, 2026·2 pages

✨ AI Summary

Zhejiang Huahai Pharmaceutical Co., Ltd. announces its subsidiary, Zhejiang Huahai Pharmaceutical Co., Ltd., has received a drug registration certificate for Upadacitinib Extended-Release Tablets from the National Medical Products Administration. This product is used for moderate-to-severe atopic dermatitis and other conditions. The certificate is valid until June 29, 2031.

Summary generated by AI · Always verify with source document

Full Translation

AI Translation· gemini_document

Securities Code: 300401

Bond Code: 123178

Securities Abbreviation: Huahai Bio

Bond Abbreviation: Huahai Convertible Bond

Announcement No.: 2026-034

Zhejiang Huahai Pharmaceutical Co., Ltd.

Announcement on Subsidiary Obtaining Drug Registration Certificate

The Company and all members of the Board of Directors guarantee that the information disclosed is true, accurate, and complete, and that there are no false records, misleading statements, or major omissions.

Zhejiang Huahai Pharmaceutical Co., Ltd. (hereinafter referred to as the "Company") announces that its wholly-owned subsidiary, Zhejiang Huahai Pharmaceutical Co., Ltd. (hereinafter referred to as "Huahai Pharmaceutical"), recently received the "Upadacitinib Extended-Release Tablets" Drug Registration Certificate approved and issued by the Nation

Free accounts get 10 full releases per month. Pro subscribers get unlimited access.